Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128954) titled 'Efficacy and Safety of Jinlong Capsule Combined with Apatinib and Camrelizumab in Patients with Resectable Primary Liver Cancer: A Preliminary, Prospective, Randomized, Controlled Clinical Study' on July 28.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences

Condition: Primary liver cancer

Intervention: Study group:Jinlong Capsule combined with neoadjuvant therapy for liver cancer

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-08-01

Target Sample Size: Study group:20;Control group:10;

Countries o...